PT-141 – Bremelanotide Research Peptide

PT-141 Peptide Research

PT-141, also known as bremelanotide, is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) and an agonist at melanocortin receptors, including MC3R and MC4R. Research has investigated PT-141 in relation to melanocortin receptor signaling, neuroendocrine pathways, and sexual-response biology.

Research Material for Laboratory Applications

PT-141 is intended for qualified laboratory and analytical research involving peptide chemistry, receptor pharmacology, melanocortin signaling, and cellular or neurobiological pathways.

Researchers can investigate PT-141 under controlled experimental conditions to examine receptor interactions, signaling responses, pharmacological properties, and other molecular characteristics.

The product should be distinguished from pharmaceutical bremelanotide formulations. The FDA identifies bremelanotide acetate and PT-141 as synonyms in its substance database, while noting that a substance listing itself does not imply regulatory approval.

Melanocortin Receptor Research

PT-141 has been studied as a melanocortin receptor agonist, with particular interest in MC3R and MC4R signaling. These receptors are involved in several physiological pathways, making PT-141 a useful research compound for investigating melanocortin receptor biology.

Laboratory studies can examine receptor activation, downstream signaling, peptide-receptor interactions, and biological responses under defined experimental conditions.

Neuroendocrine and Sexual-Response Research

Experimental research has investigated PT-141 in relation to sexual-response pathways. Early clinical studies evaluated bremelanotide in men and women, while later Phase 3 research evaluated bremelanotide in premenopausal women with acquired, generalized hypoactive sexual desire disorder.

Importantly, these clinical findings relate to the approved pharmaceutical use of bremelanotide and should not be interpreted as establishing that a research-grade PT-141 product is safe, effective, or appropriate for human administration.

Regulatory Context

Bremelanotide is the active ingredient in Vyleesi, which received FDA approval in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The FDA labeling specifically states that Vyleesi is not indicated for men, postmenopausal women, or enhancement of sexual performance.

Therefore, a research-grade PT-141 product should be clearly distinguished from the FDA-approved pharmaceutical formulation and should not be marketed as an approved treatment.

Laboratory Research Use Only

PT-141 is offered as research material for qualified scientific and analytical applications. It is not intended to replace an approved prescription medicine and should not be presented as a treatment, dietary supplement, or general-purpose sexual-performance product.

Researchers should handle, store, and analyze PT-141 according to applicable laboratory procedures, institutional safety requirements, and validated analytical protocols.

Important Research Notice

PT-141 is intended for scientific research and analytical purposes. Published research and FDA-approved uses of pharmaceutical bremelanotide should not be interpreted as establishing the safety, quality, or suitability of a particular research-grade product for human or veterinary use.